Craig-Hallum Bullish on Ironwood Pharmaceuticals (IRWD), Keeps Buy Rating

On the aforesaid day, Citizens expert Jason Butler upgraded Ironwood Pharmaceuticals from Market Perform to Outperform with an $8 terms target. This sentiment was posted arsenic the steadfast cited restored assurance successful the halfway spot of Linzess. Butler noted that the drug’s show eases concerns regarding the company’s indebtedness obligations and allows for a renewed absorption connected the semipermanent worth of its pipeline asset, apraglutide.

Butler estimates that Linzess could make astir $1.5 cardinal successful marque nett for Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) earlier its nonaccomplishment of exclusivity. According to the firm’s probe note, the currency travel from this plus is expected to beryllium much than capable to conscionable the company’s existing indebtedness requirements.

Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is simply a biotechnology institution that develops and commercializes therapies for gastrointestinal and uncommon diseases successful the US and internationally.

While we admit the imaginable of IRWD arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.